<DOC>
	<DOCNO>NCT00099996</DOCNO>
	<brief_summary>This study test safety effectiveness 40 mg ezetimibe ( Zetia ) daily lower blood level cholesterol plant sterol sitosterol campesterol patient homozygous sitosterolemia , inherit disorder sterol metabolism . ( Sterols alcohol substance find animal plant fat . ) In disorder , excess many plant sterol absorb enough excrete . Patients develop atherosclerosis coronary heart disease early childhood , well problem include arthritis , arthralgia , tendon xanthoma ( lipid deposit ) . Current treatment consist ezetimibe 10 mg , dietary restriction plant shellfish sterol , bile salt bind resin . Ezetimibe cholesterol-lowering drug inhibits intestinal absorption cholesterol structurally related plant sterol across intestinal wall . Patients homozygous sitosterolemia 18 85 year age complete NHLBI 's 1-year study ezetimibe 10 mg day may eligible study . All participant maintain current stable diet take 10-mg pill ezetimibe daily 26 week . They also randomly select take either additional 30-mg pill ezetimibe placebo ( look-alike pill active ingredient ) . Patients fast least 12 hour 6 visit schedule course study . At visit , patient undergo follow procedure monitor health evaluate response treatment : - Medical history review medication - Physical examination - Measurement vital sign ( pulse rate , blood pressure , breathe rate temperature ) - Review dietary maintenance - Measurements height , weight , waist circumference - Measurement ( ruler ) photograph non-Achilles xanthoma - X-ray Achilles tendon - Blood draw urine collection - Pregnancy test woman childbearing potential</brief_summary>
	<brief_title>Higher-Dose Ezetimibe Treat Homozygous Sitosterolemia</brief_title>
	<detailed_description>Homozygous Sitosterolemia inherit , autosomal recessive disorder sterol metabolism . Patients homozygous sitosterolemia experience accelerate atherosclerosis initial coronary heart disease ( CHD ) event occur childhood . Plasma concentration sitosterol dietary plant sterol markedly elevate homozygous sitosterolemic patient , characteristic disorder . Sitosterolemic individual demonstrate range abnormality sterol absorption , metabolism , excretion . Recent report show sitosterolemia result mutation 1 2 ATP-binding cassette half-transporters ( ABCG5 ABCG8 ) , responsible regulation non-cholesterol sterol body . Current treatment homozygous sitosterolemia consist ezetimibe 10 mg , dietary restriction plant shellfish sterol , well use bile salt binding resin . Ezetimibe first member new class cholesterol-lowering agent inhibit intestinal absorption cholesterol structurally-related noncholesterol sterol ( plant sterol ) across intestinal wall . Importantly , ezetimibe inhibitor inducer CYP450 , reduce potential drug-drug interaction render ezetimibe particularly appeal candidate drug . Ezetimibe prove generally safe well-tolerated monotherapy coadministered statin , overall clinical adverse experience profile similar placebo . In clinical study hypercholesterolemic patient , ezetemibe dos range 0.25 40 mg daily period 8 12 week effective placebo lower plasma TC LDL-C concentration . There dose-related increase adverse experience laboratory abnormality study . We investigate whether high dose ezetimibe safe efficacious lowering plant sterols patient sitosterolemia .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>INCLUSION CRITERIA : To enrol study , patient must meet following criterion : 1 . Patient least 18 year age great 85 year age Visit 1 . 2 . Patient diagnosis homozygous sitosterolemia , history plasma sitosterol concentration great 5 mg/dL ( 0.13 mmol/L ) . 3 . Patient ongoing stable regimen ezetimibe 10 mg daily least 6 month prior Visit 1 . 4 . If patient currently treatment sitosterolemia ( addition ezetimibe 10 mg ) , treatment regimen must stable least 4 week prior visit 1 . Note : Treatments may include bile salt binding resin , statin , and/or apheresis . 5 . Patient must willing maintain current treatment regimen duration study . 6 . Patient must stable diet least 4 week prior visit 1 . 7 . Patient must willing maintain diet duration study . 8 . Patient man postmenopausal woman . Patient premenopausal woman either surgically sterilize highly unlikely conceive , negative urine betahCG pregnancy test within 72 hour prior start study treatment . Note : Highly unlikely conceive define woman : ( 1 ) vasectomize partner , ( 2 ) copper intrauterine device ( IUD ) place great 3 month without complaint , ( 3 ) abstain heterosexual intercourse , ( 4 ) agrees use doublebarrier method contraception , ( 5 ) use noncyclical oral contraceptive . EXCLUSION CRITERIA : 1 . Patient condition , opinion investigator , might pose risk patient , interfere participation study , meet criterion protocol . MEDICAL HISTORY AND LABORATORY ABNORMALITIES PRIOR TO RANDOMIZATION : 2 . Patient clinically significant laboratory abnormality visit 1 and/or last available laboratory result prior visit 2 : i. ALT ( SGPT ) great equal 3 x ULN ( 75 mU/mL 75 IU/L ) . ii . AST ( SGOT ) great equal 3 x ULN ( 66 mU/mL 66 IU/L ) . iii . TSH great 6 microIU/mL 6mIU/L change medication hypothyroidism within 6 week prior visit 1. iv . CPK great equal 3 x ULN ( 360 mg/dL 360 IU/L ) persistent elevation redraw muscle symptom consistent myopathy . c. Patient know hypersensitivity contraindication ezetimibe . d. Patient breast feeding . e. Patient 's weight le 40 kg . f. Patient treat investigational drug within 30 day prior visit 1 . PROHIBITED MEDICAL CONDITIONS : g. Patient uncontrolled cardiac arrhythmia . h. Patient unstable angina pectoris within 1 month visit 1. . Patient severe/unstable peripheral vascular disease . j . Patient symptomatic carotid disease ( transient ischemic attack , stroke ) within 1 month visit 1. k. Patient myocardial infarction within 1 month visit 1. l. Patient coronary artery bypass surgery , invasive coronary procedure within 1 month visit 1. m. Patient poorly control Type 1 Type 2 diabetes mellitus ( HbA1c visit 1 great 10 % ) , antidiabetic regimen change within 8 week prior visit 1. n. Patient uncontrolled hypertension ( systolic BP great 180 mm Hg and/or diastolic BP great 110 mm Hg ) . . Patient impaired renal function ( creatinine great 2.0 mg/dL 176.80 micromol/L ) , nephritic syndrome Visit 1. p. Patient active chronic hepatobiliary disease hepatic disease . q . Patient known positive human immunodeficiency ( HIV ) . r. Patient history severe psychiatric illness , drug/alcohol abuse within past 5 year , major psychiatric illness adequately control stable pharmacotherapy . s. Patient cancer within past 5 year ( except successfully treat basal squamous cell carcinoma skin ) . CONCOMITANT MEDICATIONS/TREATMENTS : t. Patient statin treat , likely require treatment , agent precaution contraindication concomitant use statin . Note : These agent include know interaction statin : antifungal azoles ( itraconazole ketoconazole ) , macrolide antibiotic ( erythromycin clarithromycin ) , nefazodone , verapamil , amiodarone , protease inhibitor . u . Patient take oral corticosteroid UNLESS patient us stable replacement therapy pituitary/adrenal disease . For indication , patient must stable regimen least 3 month prior visit 1. v. Patient thiazide diuretic UNLESS treat stable regimen least 6 week prior visit 1 , expect remain stable duration study . w. Patient ileal bypass surgery within 3 month prior visit 1. x . Patient currently take margarine contain phytosterols/phytostanols supplements/medications know increase sitosterol campesterol concentration .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>Sitosterolemia</keyword>
	<keyword>Sitosterol</keyword>
	<keyword>Ezetimibe</keyword>
	<keyword>Absorption</keyword>
	<keyword>Intestine</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Homozygous Sitosterolemia</keyword>
</DOC>